We believe in abetter future forpeople and theplanet.
At Sofinnova Partners, we focus on breakthrough innovations that have the potential to solve the world's most pressing problems. Experience, agility, and diverse points of view push us forward, driving our ability to evolve in a complex environment.
“Partners for Life” is a cornerstone of our identity: nurturing strong relationships through trust and transparency. We invest in people and science to create opportunity. We commit to long-term partnerships with entrepreneurs who are as passionate as we are about pushing the frontiers of innovation to contribute to a better future.
Founded in 1972, Sofinnova Partners has backed more than 500 companies over 50 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management.
Sofinnova Partners is active across the entire value chain of life sciences investments, from seed to later-stage, with a focus on healthcare and sustainability. Each of our funds is a manifestation of our ability to recognize opportunity and unlock its potential with a dedicated team and a tailored strategic approach.
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
Years of Experience
Euros in Assets Under Management
Distinct Fund Strategies
"We are known for being company creators. We continue to do what we know. Our strategy has evolved, but has remained consistent."
"If you treat patients, you save lives, ultimately this is going to be good for investors. We believe that by backing companies, whether early stage or later stage, that bring a product to patients — ultimately this translates into financial return."
“We have experience, a strong network, a good reputation for adding value to our portfolio companies — and the relationships between the CEOs of the portfolio companies and our partners are excellent.”
“I joined Sofinnova Partners because first of all, they have a fantastic brand in Europe, but it's easy to see it is a very strong partnership. They're loyal to each other and everyone knows they treat entrepreneurs well.”
Sofinnova Partners Announces New Investment In Nanophoria, Developer Of An Innovative Non-viral Drug Delivery Platform
NodThera announces clinical progress for lead NLRP3 inflammasome inhibitors and candidate selection of novel brain-penetrant compound
GFBiochemicals raises €15m series A to advance its mission to end chemical pollution
Asceneuron awarded second grant from The Michael J. Fox Foundation for accelerated research into novel Parkinson’s disease therapies
Enthera Pharmaceuticals appoints Aled Williams as Chief Executive Officer